Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.31 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.30 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329052 | 0.97 | APP (0.46) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL28621315 | 0.95 | APP (0.44) | APPLMNABLMPTGS1PDE4A | |
| Ammonia Solution, Strong SCHEMBL18008289 | 0.95 | APP (0.44) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL21483589 | 0.91 | APP (0.41) | APPLMNABLMPTGS1PDE4A | |
| Dimethylamine SCHEMBL18008742 | 0.91 | APP (0.41) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL5637565 | 0.90 | APP (0.44) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL10045748 | 0.89 | LMNA (0.54) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL2240223 | 0.89 | LMNA (0.54) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL25358063 | 0.88 | APP (0.42) | APPLMNABLMPTGS1PDE4A | |
| SCHEMBL9019490 | 0.88 | APP (0.42) | APPLMNABLMPTGS1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | APP 2556/4885LMNA 3775/4885BLM 3747/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | APP 3306/4885LMNA 3461/4885BLM 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.